Ach-Ezetimibe · DIN 02425610 · 10 mg · tablet
Limited Use, Reason for Use code 380, 381 requiredMarketed · checked November 20, 2026
StatusLimited Use, Reason for Use code 380, 381 required
Write on scriptone applicable Reason for Use code, 380 or 381 (criteria below)
Patient paysIf the Reason for Use code is written and the criteria are met, ODB 65 and over pays:
• ODB senior: $100/program-year deductible
• Then up to $6.11 per prescription
• Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
If the criteria are not met, ODB does not pay this product under Limited Use. [Limited Use benefit, Formulary flag]
Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.
Ontario Limited Use criteria, code 380, 381
Reason for Use code 380
For use in combination with a HMG-CoA reductase inhibitor ('statin') in patients with hypercholesterolemia who have not reached target LDL levels despite the use of maximally tolerated doses.
Coverage limit:
LU Authorization Period: Indefinite
Reason for Use code 381
For use as monotherapy in the management of hypercholesterolemia in patients who are intolerant to HMG-CoA reductase inhibitors or where HMG-CoA reductase inhibitors are contraindicated.
Coverage limit:
LU Authorization Period: Indefinite
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Ach-Ezetimibe · DIN 02425610
Manufacturer: Accord Healthcare Inc.; listing date 2014-11-27
Health Canada: Marketed since 2014-09-17 · brand ACH-EZETIMIBE · ATC C10AX09 EZETIMIBE · form Tablet · route Oral · ingredients EZETIMIBE 10 MG · company Accord healthcare inc · schedule Prescription
Ach-Ezetimibe: Formulary list price $0.18 per unit (the source does not state the unit; exact figure $0.1811). What the ministry pays, not the patient.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02425610)
Source record
DIN 02425610: Ach-Ezetimibe
Raw flags: chronicUseMed=Y, sec12=Y, sec3=Y
Item: 240600049; group id 302; item number 0656; lccId 00150; manufacturer id ACH
Source form: Tab; strength: 10mg
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.1811; ministry $0.1811
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02425610
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=91025
Interchangeable products
AG-Ezetimibe · DIN 02475898 · $0.1811
Act Ezetimibe · DIN 02414716 · $0.1811
Apo-Ezetimibe · DIN 02427826 · $0.1811
Auro-Ezetimibe · DIN 02469286 · $0.1811
Bio-Ezetimibe · DIN 02425211 · $0.1811
Ezetimibe · DIN 02429659 · $0.1811
Ezetimibe · DIN 02431300 · $0.1811
Ezetrol · DIN 02247521 · $0.1811
GLN-Ezetimibe · DIN 02460750 · $0.1811
Jamp-Ezetimibe · DIN 02423235 · $0.1811
M-Ezetimibe · DIN 02467437 · $0.1811
Mar-Ezetimibe · DIN 02422662 · $0.1811
Mint-Ezetimibe · DIN 02423243 · $0.1811
NRA-Ezetimibe · DIN 02481669 · $0.1811
NRA-Ezetimibe Tablets · DIN 02536420 · $0.1811
PMS-Ezetimibe · DIN 02416409 · $0.1811
Ran-Ezetimibe · DIN 02419548 · $0.1811
Sandoz Ezetimibe · DIN 02416778 · $0.1811
Teva-Ezetimibe · DIN 02354101 · $0.1811
Shortage status: not checked (no credentials)